Nvidia Corp’s Recursion Pharmaceuticals RXRX Stock Holding History

Nvidia Corp’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,706,363	Closed	-$37.6M	–	8
2025 Q3	$37.6M	Hold	7,706,363	–	–	0.98%	5
2025 Q2	$39M	Hold	7,706,363	–	–	0.9%	5
2025 Q1	$40.8M	Hold	7,706,363	–	–	3.55%	4
2024 Q4	$52.1M	Hold	7,706,363	–	–	17.11%	3
2024 Q3	$50.8M	Hold	7,706,363	–	–	11.73%	3
2024 Q2	$57.8M	Hold	7,706,363	–	–	14.7%	2
2024 Q1	$76.8M	Hold	7,706,363	–	–	23.09%	2
2023 Q4	$76M	Buy	+7,706,363	New	+$55M	32.98%	2

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Nvidia Corp's RXRX Position: Q4 2025 in Review

Nvidia Corp sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 7,706,363 shares — an estimated $37.6M sold.

Nvidia Corp first reported a position in RXRX in Q4 2023 and held it in 8 quarters. The position peaked at $76.8M in Q1 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Nvidia Corp reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Nvidia Corp sold 7,706,363 Recursion Pharmaceuticals shares in Q4 2025, an estimated $37.6M.
Nvidia Corp first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Nvidia Corp's Recursion Pharmaceuticals position peaked at $76.8M in Q1 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Nvidia Corp's 13F filing for Q4 2025, filed 17 Feb 2026.